BARONI, Marcello
 Distribuzione geografica
Continente #
NA - Nord America 4.595
AS - Asia 2.242
EU - Europa 1.494
SA - Sud America 420
AF - Africa 40
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 8.806
Nazione #
US - Stati Uniti d'America 4.472
SG - Singapore 931
CN - Cina 639
IT - Italia 365
BR - Brasile 340
DE - Germania 303
HK - Hong Kong 210
GB - Regno Unito 172
UA - Ucraina 170
VN - Vietnam 167
TR - Turchia 112
PL - Polonia 93
FI - Finlandia 69
RU - Federazione Russa 68
CA - Canada 64
SE - Svezia 63
ID - Indonesia 48
MX - Messico 47
FR - Francia 37
AR - Argentina 32
NL - Olanda 32
IN - India 31
BE - Belgio 30
ES - Italia 28
JP - Giappone 24
BD - Bangladesh 23
ZA - Sudafrica 21
EC - Ecuador 19
CZ - Repubblica Ceca 18
AT - Austria 12
LT - Lituania 12
PE - Perù 12
AU - Australia 11
IQ - Iraq 8
PK - Pakistan 8
MA - Marocco 7
AZ - Azerbaigian 6
CO - Colombia 6
RO - Romania 6
KE - Kenya 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
GE - Georgia 3
GT - Guatemala 3
IR - Iran 3
PY - Paraguay 3
TN - Tunisia 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
EU - Europa 2
HN - Honduras 2
HU - Ungheria 2
IE - Irlanda 2
JO - Giordania 2
KR - Corea 2
MY - Malesia 2
PT - Portogallo 2
SA - Arabia Saudita 2
SN - Senegal 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 8.806
Città #
Singapore 557
Ashburn 457
Fairfield 383
Woodbridge 361
Chandler 274
Beijing 242
Santa Clara 231
Houston 213
Hong Kong 208
Dallas 202
Ann Arbor 190
Ferrara 180
Jacksonville 168
Seattle 167
Wilmington 152
Cambridge 123
Munich 92
New York 92
The Dalles 92
Warsaw 87
Los Angeles 84
Boardman 76
Izmir 66
Nanjing 59
Princeton 56
Ho Chi Minh City 50
Jakarta 41
Milan 40
Dearborn 37
Hanoi 37
Shanghai 36
Bremen 32
Mexico City 32
São Paulo 32
San Diego 31
Brooklyn 26
Brussels 25
Falls Church 23
Nanchang 22
Shenyang 22
Tokyo 22
Turku 22
Hefei 21
London 19
Orem 19
Buffalo 18
Denver 18
Montreal 18
Toronto 18
Moscow 17
Poplar 17
Brno 16
Chicago 16
Redwood City 16
Florence 15
Hebei 14
Helsinki 14
Johannesburg 14
Norwalk 14
Dong Ket 13
Frankfurt am Main 13
Manchester 13
Amsterdam 12
Boston 12
Guangzhou 12
Jiaxing 12
Tianjin 12
Mcallen 11
Rome 11
Chennai 10
Phoenix 10
Verona 10
Zhengzhou 10
Atlanta 9
Columbus 9
Düsseldorf 9
Haiphong 9
San Francisco 9
San Mateo 9
Montréal 8
Quito 8
Auburn Hills 7
Bologna 7
Des Moines 7
Dortmund 7
Lima 7
Rio de Janeiro 7
Stockholm 7
Abdullah 6
Ankara 6
Augusta 6
Baku 6
Biên Hòa 6
Changsha 6
Charlotte 6
Easley 6
Mumbai 6
North Bergen 6
Ottawa 6
Ribeirão Preto 6
Totale 5.978
Nome #
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 246
Hemostasis biomarkers in multiple sclerosis 231
Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis 222
Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. 211
Tissue factor and coagulation factor VII levels during acute myocardial infarction: Association with genotype and adverse events 207
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 207
Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis 201
Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants 195
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 184
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 184
TRATTAMENTO E PREVENZIONE DI MALATTIE CARDIOVASCOLARI CON ACIDO ERUCICO E METODI DIAGNOSTICI CORRELATI 183
Molecular bases of type II protein S deficiency: the I203-D204 deletion in the EGF4 domain alters GLA domain function 181
Membrane binding and anticoagulant properties of protein S natural variants 180
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 180
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 170
Plasma levels of soluble NCAM in multiple sclerosis 167
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 165
Human protein S circulates in plasma partially bund to LDL and HDL: do PS-lipoprotein complexes mediate PS delivery within atherosclerotic plaque? 162
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 160
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation 155
Tissue Factor and Coagulation Factor VII Levels during Acute Myocardial Infarction Contribute to Predict Mortality and re-infarction. 154
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 154
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 149
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 148
Impaired prothrombinase activity of factor X Gly381 Asp results in severe familial CRM+ FX deficiency 143
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis 140
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 140
Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors 140
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 135
Reduced activation of the Gla19Ala FX variant via the extrinsic coagulation pathway results in symptomatic CRMred FX deficiency 133
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 130
Release of Tissue Factor-bearing microparticles by human dendritic cells induced by stimulation of membrane P2X7 receptors 127
Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients 127
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods 126
Protein S on the surface of plasma lipoproteins: a potential mechanism for protein S delivery to the atherosclerotic plaques? 124
Non-conventional therapeutic strategies for inherited disorders of hemostasis 122
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 121
Hemostasis gene expression of the internal jugular and saphenous veins 121
CCL18 plasma levels are increased in progressive MS patients and associated with MRI outcomes of tissue injury (P1.396) 117
THE NATURAL ARG386CYS MUTATION IN THE COAGULATION FACTOR X, AS A TOOL TO INVESTIGATE DIFFERENT FX-REQUIREMENTS IN INITIATION AND PROPAGATION PHASES. 116
Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis 114
In Situ Endothelial SARS-CoV-2 Presence and PROS1 Plasma Levels Alteration in SARS-CoV-2-Associated Coagulopathies 110
Natural mutations in the EGF4 domain of protein S produce extended conformational changes and alter phospholipid and C4bBP interactions 104
Tratamiento y profilaxis de trastornos cardiovasculares con ácido erúcico 100
EFFECT OF SARS-CoV-2 ON THE COAGULATION CASCADE IN COVID-19 ASSOCIATED COAGULOPATHIES 99
Basophil Blood Cell Count Is Associated With Enhanced Factor II Plasma Coagulant Activity and Increased Risk of Mortality in Patients With Stable Coronary Artery Disease: Not Only Neutrophils as Prognostic Marker in Ischemic Heart Disease 97
West Nile virus non-structural protein 1 promotes amyloid Beta deposition and neurodegeneration 95
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis 94
null 94
The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII 94
NATURAL MUTATIONS IN THE EGF4 DOMAIN OF PROTEIN S PRODUCE EXTENDED CONFORMATIONAL CHANGES AND ALTER PHOSPHOLIPID AND C4BBP INTERACTIONS 93
null 93
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 92
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease 92
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 89
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods 84
Molecular characterization of factor X deficiency associated with borderline plasma factor X level 84
null 84
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods 78
null 73
Plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (P3.368) 71
Mapping of inhibitory antibodies directed to the carboxy-terminus of FVIIa in severe FVII deficiency with elongated C-terminal variant (p.A354V-p.P464Hfs†) 70
Coagulation factor VII variants resistant to inhibitory antibodies 69
Immune response to treatment in a severe factor VII deficient patient: characterization of the inhibitory antibody and epitope-mapping 66
Suppression of “leaky” nonsense mutations by ribosome readthrough accounts for residual factor IX levels in Haemophilia B patients 65
Coagulation factor VII variants resistant to inhibitory antibodies. 62
null 56
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods 53
Relationships among circulating levels of hemostasis inhibitors, chemokines, adhesion molecules, and mri characteristics in multiple sclerosis 53
null 45
Natural Mutations in the 4th EGF-Like Domain of Protein S Alter GLA and SHBG Domain Interactions. 18
Selected cell receptor genotypes differentially modulate the ABO blood group influence on Factor VIII levels in severe aortic stenosis 15
Flavivirus Nonstructural Protein 1-Driven Coagulation via Tissue Factor-Bearing Microvesicles: A Pilot Study 5
Totale 8.969
Categoria #
all - tutte 42.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.501


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021582 0 0 0 0 0 58 81 80 50 145 123 45
2021/2022636 84 70 22 28 24 29 26 35 18 49 44 207
2022/2023634 60 64 23 87 92 88 46 50 67 8 37 12
2023/2024436 27 33 15 10 32 64 22 48 12 16 10 147
2024/20251.565 33 41 143 47 170 153 33 61 254 210 235 185
2025/20262.800 491 249 476 626 756 202 0 0 0 0 0 0
Totale 8.969